{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:47:41Z","timestamp":1791499661079,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Henan Province Innovation Talents of Science and Technology Plan"},{"name":"Research Team Fund","award":["184200510020"],"award-info":[{"award-number":["184200510020"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.intimp.2020.106245","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T06:23:24Z","timestamp":1582266204000},"page":"106245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma"],"prefix":"10.1016","volume":"82","author":[{"given":"Tianyu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengxuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2020.106245_b0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.intimp.2020.106245_b0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(08)70072-X","article-title":"Screening for gastric cancer in Asia: current evidence and practice","volume":"9","author":"Leung","year":"2008","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106245_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0895-4356(02)00534-6","article-title":"Gastric cancer epidemiology and risk factors","volume":"56","author":"Kelley","year":"2003","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106245_b0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semradonc.2012.09.008","article-title":"Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease","volume":"23","author":"Buas","year":"2013","journal-title":"Semin. Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106245_b0025","first-page":"577","article-title":"Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach","volume":"180","author":"Ohno","year":"1995","journal-title":"J. Am. Coll. Surg."},{"issue":"3","key":"10.1016\/j.intimp.2020.106245_b0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00000658-200009000-00007","article-title":"Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical\/topographic classification in 1,002 consecutive patients","volume":"232","author":"Rudiger Siewert","year":"2000","journal-title":"Ann. Surg."},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2020.106245_b0035","doi-asserted-by":"crossref","first-page":"ii31","DOI":"10.1093\/annonc\/mdg726","article-title":"Gastric cancer: epidemiology, pathology and treatment","volume":"14","author":"Alberts","year":"2003","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106245_b0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00000658-198007000-00010","article-title":"Adenocarcinoma of the gastric cardia. The choice of gastrectomy","volume":"192","author":"Papachristou","year":"1980","journal-title":"Ann. Surg."},{"issue":"7","key":"10.1016\/j.intimp.2020.106245_b0045","first-page":"423","article-title":"Prognostic differences of adenocarcinoma arising from the cardia and the upper third of the stomach","volume":"59","author":"Nakane","year":"1993","journal-title":"Am. Surg."},{"key":"10.1016\/j.intimp.2020.106245_b0050","article-title":"Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial","author":"Doi","year":"2018","journal-title":"Gastric Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2020.106245_b0055","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/gutjnl-2015-310839","article-title":"Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma","volume":"66","author":"Thompson","year":"2017","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.intimp.2020.106245_b0060","doi-asserted-by":"crossref","first-page":"771","DOI":"10.21037\/jgo.2016.08.06","article-title":"The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1","volume":"7","author":"Jin","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106245_b0065","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.intimp.2020.106245_b0070","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2020.106245_b0075","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune-checkpoint blockade: response evaluation and biomarker development","author":"Nishino","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2020.106245_b0080","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1046\/j.1365-2168.1999.01197-15.x","article-title":"Classification of adenocarcinoma of the oesophagogastric junction","volume":"86","author":"Maric","year":"1999","journal-title":"Br. J. Surg."},{"issue":"11","key":"10.1016\/j.intimp.2020.106245_b0085","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","article-title":"Classification of adenocarcinoma of the oesophagogastric junction","volume":"85","author":"Siewert","year":"1998","journal-title":"Br. J. Surg."},{"issue":"11","key":"10.1016\/j.intimp.2020.106245_b0090","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.18632\/oncotarget.1542","article-title":"Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine","volume":"4","author":"Wrangle","year":"2013","journal-title":"Oncotarget"},{"issue":"26","key":"10.1016\/j.intimp.2020.106245_b0095","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.intimp.2020.106245_b0100","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.intimp.2020.106245_b0105","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"19","key":"10.1016\/j.intimp.2020.106245_b0110","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"5 Pt A","key":"10.1016\/j.intimp.2020.106245_b0115","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.bbadis.2018.03.002","article-title":"PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras\/Erk\/EMT activation","volume":"1864","author":"Qiu","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.intimp.2020.106245_b0120","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fonc.2019.01347","article-title":"The binding of PD-L1 and Akt facilitates glioma cell invasion upon starvation via Akt\/Autophagy\/F-actin signaling","volume":"9","author":"Chen","year":"2019","journal-title":"Front. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919328255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919328255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:33:37Z","timestamp":1727454817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919328255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":24,"alternative-id":["S1567576919328255"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106245","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106245"}}